CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4”) (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the pricing of its initial public offering of 6,820,000 shares of its common stock at an initial public offering price of $11.00 per share. All of the shares are being offered by CAMP4. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.0 million. CAMP4’s common stock is expected to begin trading on the Nasdaq Global Market on October 11, 2024, under the ticker symbol “CAMP”. The offering is expected to close on October 15, 2024, subject to the satisfaction of customary closing conditions. In addition, CAMP4 has granted the underwriters a 30-day option to purchase up to an additional 1,023,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
J.P. Morgan, Leerink Partners, Piper Sandler and William Blair are acting as joint book-running managers for the offering.
A registration statement relating to the shares being sold in the offering has been filed with the U.S. Securities and Exchange Commission …
Full story available on Benzinga.com
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4”) (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the pricing of its initial public offering of 6,820,000 shares of its common stock at an initial public offering price of $11.00 per share. All of the shares are being offered by CAMP4. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.0 million. CAMP4’s common stock is expected to begin trading on the Nasdaq Global Market on October 11, 2024, under the ticker symbol “CAMP”. The offering is expected to close on October 15, 2024, subject to the satisfaction of customary closing conditions. In addition, CAMP4 has granted the underwriters a 30-day option to purchase up to an additional 1,023,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
J.P. Morgan, Leerink Partners, Piper Sandler and William Blair are acting as joint book-running managers for the offering.
A registration statement relating to the shares being sold in the offering has been filed with the U.S. Securities and Exchange Commission …
Full story available on Benzinga.com
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4”) (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the pricing of its initial public offering of 6,820,000 shares of its common stock at an initial public offering price of $11.00 per share. All of the shares are being offered by CAMP4. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.0 million. CAMP4’s common stock is expected to begin trading on the Nasdaq Global Market on October 11, 2024, under the ticker symbol “CAMP”. The offering is expected to close on October 15, 2024, subject to the satisfaction of customary closing conditions. In addition, CAMP4 has granted the underwriters a 30-day option to purchase up to an additional 1,023,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
J.P. Morgan, Leerink Partners, Piper Sandler and William Blair are acting as joint book-running managers for the offering.
A registration statement relating to the shares being sold in the offering has been filed with the U.S. Securities and Exchange Commission …Full story available on Benzinga.com Read MoreCAMP, News, IPOs, Press Releases IPOs
